In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:

• Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors
• Considerations in therapy selection for previously treated CLL
• Novel strategies for treating CLL
   

Presenters:

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.

Link to full program including downloadable slides: 
https://bit.ly/49YxtSq